At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II/III Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Sandostatin LAR With Placebo in Patients With Advanced G1-G2 Neuroendocrine Tumours (WHO 2010) of Non-pancreatic Origin
In Brief
A Phase 3 clinical trial evaluating Axitinib, Sandostatin LAR, and 1 other intervention for Neuroendocrine Tumors and Advanced Cancer. Completed, enrolled 256 participants across 26 sites in 4 countries.
Detailed Summary
Assess whether therapy with axitinib, a potent angiogenic inhibitor of the tyrosine kinase receptors of VEGF bioavailable by oral administration, is capable of improving PFS in patients with advanced G1-G2 NETs of nonpancreatic origin with progressive disease documented in the 12 months prior to entering the study.
Study Details
Timeline
Interventions
Orally, 5mg, twice daily, until progression or until unacceptable toxicity, with or without food intake.
Intramuscular, 30mg, single injection every 28 days, until disease progression or unacceptable toxicity
orally, twice daily, until disease progression or unacceptable toxicity, with or without food intake.